Investigations

GRABAR LAW OFFICE INVESTIGATES AGAINST OFFICERS OF PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX)

Pacira Biosciences, Inc. (NASDAQ: PCRX) is a pharmaceutical company committed to developing and providing non-opioid pain management and regenerative health solutions. Pacira currently offers three commercial-stage non-opioid treatments, including Exparel.

A recently filed securities fraud class action complaint alleges that Pacira, via certain of its officers, disseminated materially false and misleading statements and/or concealed material adverse facts concerning the validity and scope of the Company's patents. On August 9, 2024, Pacira announced that the New Jersey District Court had invalidated its ‘495 patent. This announcement surprised investors and analysts alike as they reacted immediately to the revelations, and the price of Pacira’s common stock declined dramatically.

Current Pacira shareholders who have held Pacira shares since prior to August 2, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

If you would like to learn more about this matter, you are encouraged to contact Joshua H. Grabar at jgrabar@grabarlaw.com or call 267-507-6085.

Please enter your name.
Please enter a valid phone number.
Please enter a message.
Send

                                                                                           Attorney Advertising Disclaimer

  • Join This Action

  • Alternatively, you may upload your transactions using the upload button below or email them to jgrabar@grabarlaw.com. *

  • Drop files here or
    Max. file size: 100 MB.
    • Clear Signature
      Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

    • Date of signing: *

    • MM slash DD slash YYYY
    • This field is for validation purposes and should be left unchanged.